Extracellular vesicles as therapeutics for inflammation and infection

Curr Opin Biotechnol. 2024 Feb;85:103067. doi: 10.1016/j.copbio.2024.103067. Epub 2024 Jan 25.ABSTRACTExtracellular vesicles (EVs) are an emergent next-generation biotechnology with broad application potential. In particular, immunomodulatory bioactivity of EVs leading to anti-inflammatory effects is well-characterized. Cell source and culture conditions are critical determinants of EV therapeutic efficacy, while augmenting EV anti-inflammatory bioactivity via diverse strategies, including RNA cargo loading and protein surface display, has proven effective. Yet, translational challenges remain. Additionally, the potential of direct antimicrobial EV functionality has only recently emerged but offers the possibility of overcoming drug-resistant bacterial and fungal infections through novel, multifactorial mechanisms. As discussed herein, these application areas are brought together by the potential for synergistic benefit from technological developments related to EV cargo loading and biomanufacturing.PMID:38277970 | DOI:10.1016/j.copbio.2024.103067
Source: Current Opinion in Biotechnology - Category: Biotechnology Authors: Source Type: research